Be the first person to write a business review for Cambridge Research & Instrumentation, Inc

Camtek Ltd. engages in the design, development, manufacture, and marketing of automated optical inspection (AOI) systems and related products. Its AOI systems are computerized systems, which optically inspect various types of electronic product components for defects caused during the manufacturing process. The company's products include Dragon systems for the inspection of various printed circuit board (PCB) types in a mass production environment; Orion systems that are AOI systems for the high volume inspection of various PCB types; and the Pegasus line, which includes systems for automated inspection of finished integrated circuit (IC) substrates that are subsequently used in packaging of ball grid array and chip scale package devices. It also offers the Mustang line that includes systems for automated inspection of finished HD panels that are subsequently used in mobile consumer electronics, such as mobile-phones, digital cameras, PDAs, and other consumer electronic devices; Planet for the inspection of ultra-fine-line IC substrate; LAM for main-stream Large Area Masks (LAM) inspection; and Automated Inspectify Center, which integrates inspection and verification into one cell. In addition, Camtek provides verification systems that enable verification of panels after inspection; and the Falcon's advanced algorithms and inspection capabilities, which enable its dedicated models to detect defects in the semiconductor die. The company primarily serves the PCB, IC substrate, and semiconductor manufacturing and packaging industries. It offers its products primarily through a distribution network in the Asia Pacific region, North America, and Europe. The company was founded in 1987 and is headquartered in Migdal Ha'Emek, Israel. Camtek Ltd. operates as a subsidiary of Prior-Tech Ltd.

CANBERRA, an AREVA Company, is the worldwide leader in nuclear measurements. With over 40 years of experience in this field, Canberra bring solutions to customers, not just products or services. Wherever you are, the CANBERRA presence is not far away. CANBERRA operates a total of 12 production and engineering facilities in the United States, France, Benelux, England, and Canada. This worldwide presence also means worldwide technologies. CANBERRA has deep, long-standing relationships with the major technology centers and research laboratories around the globe. This rich diversity of technologies and personnel helps Canberra offer a broad range of best available technologies - tailored to local needs and regulations. In addition, sales and service capability exists in virtually every country of the globe. Our 1000+ employees all operate with a single focus - to bring the very best nuclear technology in the world to your operation.

Celera Corporation delivers personalized disease management through a combination of products and services. It operates in three segments: Lab Services, Products, and Corporate. The Lab Services segment offers clinical laboratory tests and disease management services for healthcare providers to enhance cardiovascular disease treatment regimens for patients. It offers clinical laboratory testing services that characterize and monitor cardiovascular disease risk, and personalized treatment and ongoing therapeutic compliance education services. The principal tests offered by this segment include LDL-S3GGE test that measures low-density lipoprotein (LDL) size as a subclass distribution divided in seven regions and characterizes the amount of LDL distributed in these regions; HDL-S10GGE test that measures high-density lipoprotein (HDL) size as a subclass distribution divided across five HDL regions and characterizes the amount of HDL distributed in these regions; Apolipoprotein E Genotypes test for lipoprotein metabolism; and Kinesin-Like Protein 6 test, which detects a variant in a gene called Kinesin-Like Protein 6. The Products segment develops and manufactures molecular diagnostic products for disease detection, prediction of disease predisposition, monitoring of disease progression and disease severity, and determination of patient responsiveness to treatments. It has a strategic alliance with Abbott Laboratories to discover, develop, and commercialize molecular diagnostic products for disease detection, prediction of disease predisposition, disease progression monitoring, and therapy selection. The Corporate segment licenses small molecule drug development programs and Life Technologies intellectual property to third parties for use in the diagnostic field; and establishes collaborations to develop cancer therapies based on its proteomics discoveries. The company was founded in 1998 and is headquartered in Alameda, California.

CEM is a company based on innovation that touches many different industries and scientific disciplines. CEM helped pioneer the field of microwave chemistry and have long been recognized for expertise on the subject through publications and awards. For more than 30 years, CEM have been designing and developing laboratory instruments and scientific methods (both microwave-based and non-microwave technologies) that are used by major companies, prestigious research institutes, and universities around the world.

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for genetic testing in the clinical molecular diagnostic, industrial, and biothreat markets. Its systems enable molecular testing for organisms and genetic-based diseases by automation. Its SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample; and GeneXpert system integrates sample preparation in addition to DNA amplification and detection. GeneXpert is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as ER and ICU units within hospitals, and doctors offices. In the clinical molecular diagnostic market, Cepheid markets tests for both the GeneXpert and the SmartCycler platforms in the areas of hospital acquired infections, critical infectious disease, immuno-compromised transplantation, women's health, and oncology. These tests include Food and Drug Administration cleared products, such as in-vitro medical devices, CE Marked, analyte specific reagents, and research use only tests. In the industrial market, the company sells its SmartCycler along with general use polymerase chain reaction reagents and reaction tubes. Cepheid has tests available for anthrax, pestis, and tullarensis in the biothreat market. The company sells its products through direct sales and distribution channels worldwide. It has strategic relationship with bioMerieux, Inc. for bioMerieux to develop DNA testing products using nucleic acid sequence-based amplification technology. The company was founded in 1996 and is headquartered in Sunnyvale, California.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.